The Notifying Party argues that this overlap will not cause a significant
impediment to effective competition on any relevant market in Denmark, because: (i) the share increment attributable to AniCura’s activities is negligible and will not affect Mars’ competitive position; (ii) there is no overlap in the manufacture of pet food (since VetPro is manufactured by a third-party pet food supplier), so the Transaction will not remove production capacity from the market; (iii) the overlap that exists is very limited, since it relates solely to the supply of branded pet food in VetFamily and AniCura clinics; and (iv) the Danish pet food market has many suppliers that will act as a competitive constraint to the merged entity.154